Cleo Diagnostics (ASX:COV) Ending Cash Position: A$9.43 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
31 GF Score
Price A$0.36
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Ending Cash Position?

Cleo Diagnostics ASX:COV +4.41% 31 Ending Cash Position is A$9.43 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Cleo Diagnostics's Ending Cash Position for the quarter that ended in Dec. 2025 was A$9.43 Mil.

Cleo Diagnostics's quarterly Ending Cash Position declined from Dec. 2024 (A$7.31 Mil) to Jun. 2025 (A$6.46 Mil) but then increased from Jun. 2025 (A$6.46 Mil) to Dec. 2025 (A$9.43 Mil).

Cleo Diagnostics's annual Ending Cash Position increased from Jun. 2023 (A$0.24 Mil) to Jun. 2024 (A$9.37 Mil) but then declined from Jun. 2024 (A$9.37 Mil) to Jun. 2025 (A$6.46 Mil).

Cleo Diagnostics Ending Cash Position Related Terms

Cleo Diagnostics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Ending Cash Position Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25 Jun26
Ending Cash Position
0.24 9.37 6.46 6.22

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial 9.37 7.31 6.46 9.43 6.22
ASX:COV
31GF Score
Cleo Diagnostics Ltd ASX:COV
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cleo Diagnostics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.373+-2.912
=6.46

Cleo Diagnostics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.461+2.965
=9.43

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$9.43 Mil mean?
Cleo Diagnostics (ASX:COV) has a Ending Cash Position of A$9.43 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Ending Cash Position too high?
Cleo Diagnostics' current Ending Cash Position is A$9.43 Mil. Overall, Cleo Diagnostics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Ending Cash Position compare to ABT and SYK?
Cleo Diagnostics' Ending Cash Position of A$9.43 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Ending Cash Position is A$9.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Ending Cash Position of A$9.43 Mil. The current Ending Cash Position is A$9.43 Mil. Cleo Diagnostics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Ending Cash Position is A$9.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
31GF Score

Get the complete analysis for ASX:COV

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.36
Price